Jonathan Soslow Archive — Page 1 of 1

(iStock)
August 26, 2026

Duchenne muscular dystrophy patients are focus of GLP-1 therapy for obesity study

The study will begin enrolling eligible patients in September. Thirty participants, ages 12 and older, will be randomized to receive either a placebo or the GLP-1 receptor agonist semaglutide.

By Jessica Pasley
August 4, 2026

Cardiomyopathy in Duchenne muscular dystrophy is focus of nearly $2M grant

The project will integrate diverse datasets and advanced quantitative approaches to better define the natural history of cardiomyopathy in Duchenne, identify key biomarkers, and support the development of tools to optimize the design and conduct of clinical trials for candidate drugs.

By Jessica Pasley
March 12, 2025

Potential therapeutic for Duchenne muscular dystrophy takes step forward

Positive findings from a clinical trial support further study of the investigational drug ifetroban to treat cardiac complications, the leading cause of death in patients with DMD.

By Leigh MacMillan
February 23, 2024

Monroe Carell Jr. Children’s Hospital at Vanderbilt begins treating patients with novel gene therapy for Duchenne muscular dystrophy

Monroe Carell Jr. Children’s Hospital at Vanderbilt’s Jonathan Soslow, MD, and Bryan Burnette, MD, recently began treating patients with a novel gene therapy for Duchenne muscular dystrophy.

By Jessica Pasley
Javion Johnson, a patient at Children’s Hospital’s Duchenne Muscular Dystrophy Clinic, holds a plaque designating the clinic as a Certified Care Center. Others on hand include from left, his father Ronnie Johnson, mother, Xavier Verge, brother, J’zarion Williams, Andrew Sokolow, MD, Bryan Burnette, MD, Jonathan Soslow, MD, Kali Barbalena and Haleigh Southern, RN.
March 31, 2022

Vanderbilt’s Duchenne Clinic first in Tennessee to be certified

The Duchenne Muscular Dystrophy Clinic at Monroe Carell Jr. Children’s Hospital at Vanderbilt has been recognized as a Certified Duchenne Care Center Program by the Parent Project Muscular Dystrophy, and is the only center in Tennessee to receive the distinction.

By Jessica Pasley
March 28, 2019

Cardiac dysfunction in DMD

The protein MMP7 is elevated in blood from patients with Duchenne muscular dystrophy who have cardiac dysfunction, suggesting that it may be a biomarker for heart disease severity.

By Leigh MacMillan